论文部分内容阅读
对４０例恶性卵巢癌瘤，４０例良性卵巢肿瘤及４０例正常健康妇女的尿半胱氨酸蛋白酶（ｕｒｉｎｅｃｙｓｔｅｉｎｐｒｏｔｉｎａｓｅ，ＵＣＰ）和血清中的癌抗原ＣＡ１２５进行了测定，对其中２８例卵巢癌患者术前及术后化疗三个疗程中的ＵＣＰ和ＣＡ１２５进行了动态观察，并与残留癌灶有无，第二次剖腹探查病理结果及对其预测复发的价值进行分析对比。结果显示：卵巢癌组ＵＣＰ活性和ＣＡ１２５值明显高于良性和正常组，其Ⅲ～Ⅳ期患者明显高于Ⅰ～Ⅱ期者，且随化疗疗程增加而逐渐下降；残留癌灶＞２ｃｍ组ＵＣＰ和ＣＡ１２５值明显高于无残留癌灶组（Ｐ＜０．０１），术后无残留癌灶组ＵＣＰ和ＣＡ１２５下降最快，而＞２ｃｍ组下降最慢；６例第二次剖腹探查者ＵＣＰ诊断复发的敏感性为８０％，特异性１００％，准确性８３％，优于同时测定的ＣＡ１２５。因此ＵＣＰ作为卵巢癌的标记物，可对卵巢癌治疗及预后进行动态监测
In 40 cases of malignant ovarian cancer, 40 cases of benign ovarian tumors and 40 normal healthy women urine urinary caspase (urine cysteinprotinase, UCP) and serum CA125 antigen was detected in 28 cases of ovarian cancer patients UCP and CA125 in three courses before and after chemotherapy were observed dynamically and compared with the presence or absence of residual cancer, the second laparotomy to explore the pathological findings and the value of its prediction of recurrence. The results showed that: UCP activity and CA125 in ovarian cancer group was significantly higher than that in benign and normal group, the patients in stage Ⅲ ~ Ⅳ were significantly higher than those in stage Ⅰ ~ Ⅱ, and gradually decreased with the increase of chemotherapy; UCP And CA125 values were significantly higher than those without residual cancer (P <0.01). UCP and CA125 were the lowest in the group without residual tumor after operation, while those in> 2cm group showed the slowest decline. Six cases with the second laparotomy The diagnostic relapse sensitivity was 80%, specificity 100%, accuracy 83%, better than the simultaneous determination of CA125. Therefore, UCP as a marker of ovarian cancer, ovarian cancer treatment and prognosis can be dynamically monitored